The mean disease onset in the mutEphA4-Fc-treated group was 123 days, which was a delay of one week, compared with that in the saline control group (mutEphA4-Fc group = 123.6 ± 6.18 days; saline group = 115.4 ± 1.83 days); however, this difference did not reach statistical significance (log-rank test for Kaplan-Meier survival plots; p = 0.15) (Fig. 1A ).
← all excerpts
Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1<sup>G93A</sup> ALS mouse model.
1
0.1500
0.1500